Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2023 Earnings Call Transcript February 6, 2024 5:00 PM ET

Company Participants

Jacquie Ross - Vice President, Investor Relations

Daniel O’Day - Chairman and Chief Executive Officer

Johanna Mercier - Chief Commercial Officer

Merdad Parsey - Chief Medical Officer

Andrew Dickinson - Chief Financial Officer

Cindy Perettie - Executive Vice President, Kite

Conference Call Participants

Tyler Van Buren - TD Cowen

Salveen Richter - Goldman Sachs

Leon Wang - Barclays

Terrence Flynn - Morgan Stanley

Umer Raffat - Evercore

Olivia Brayer - Cantor Fitzgerald

Geoff Meacham - Bank of America

Michael Yee - Jefferies

Chris Schott - JPMorgan

Brian Abrahams - RBC Capital Markets

Operator

Good afternoon. Thank you for attending the Four Quarter and Full Year 2023 Gilead Sciences Earning Conference Call. My name is Victoria, and I'll be your moderator today. All lines will be muted during the presentation portion of the call with the opportunity for questions and answers at the end.

I would now like to pass the conference over to your host, Jacquie Ross. Thank you. You may proceed, Jacquie.

Jacquie Ross

Thank you, Operator, and good afternoon, everyone. Just after market close today, we issued a press release with earnings results for the fourth quarter and full year of 2023. The press release, slides, and supplementary data are available on the Investors section of our website at gilead.com.

The speakers on today’s call will be our Chairman and Chief Executive Officer, Daniel O’Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Merdad Parsey; and our Chief Financial Officer, Andrew Dickinson. After that, we’ll open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite.

Before we get started, let me remind you that we will be making forward-looking statements, including those related to Gilead’s business, financial condition and results of operations, plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital, and 2024 financial guidance, all of which involve certain assumptions, risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements. A description of these risks can be found in the earnings press release and our latest SEC disclosure documents. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. Non-GAAP financial measures will be used to help you understand the company’s underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, in our supplementary data sheet, as well as on the Gilead website.